Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

Inclusion criteria

• ✓. 18 years old ≤ age ≤ 70 years old, male or female not limited;
• ✓. ECOG PS score 0-1 points;
• ✓. Patients who have not received systematic treatment in the past and agree to undergo radical surgery; Patients without surgical contraindications judged by thoracic surgeons;
• ✓. Stage II, IIIA, or selective IIIB (T3N2M0 only) squamous or non squamous cell non-small cell lung cancer confirmed by histopathology or cytology and judged by researchers to be capable of undergoing R0 surgical resection for the purpose of cure. Disease staging should be based on the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) NSCLC staging system, 8th edition;
• ✓. There is sufficient tumor tissue to detect PD-L1 expression level and PD-L1 ≥ 1%;
• ✓. At least one measurable lesion (according to RECIST 1.1 criteria);
• ✓. The expected survival period is at least 12 weeks;
• ✓. Other major organs (liver, kidney, blood system, etc.) are functioning well:

Exclusion criteria